Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:diamino acid
go back to main search page
Accession:CHEBI:35987 term browser browse the term
Definition:Any amino acid carrying two amino groups.
Synonyms:cyclic_relationship: is_conjugate_acid_of CHEBI:59561


show annotations for term's descendants           Sort by:
 
L-homoarginine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Slco4c1 solute carrier organic anion transporter family, member 4C1 increases export ISO SLCO4C1 protein results in increased export of Homoarginine CTD PMID:30865704 NCBI chr 9:104,301,935...104,350,262
Ensembl chr 9:104,299,277...104,350,308
JBrowse link
L-lysine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Egf epidermal growth factor multiple interactions EXP [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine] CTD PMID:22689575 NCBI chr 2:68,820,616...68,895,537 JBrowse link
lisinopril dihydrate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme decreases activity ISO Lisinopril analog results in decreased activity of ACE protein CTD PMID:22200082 NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
JBrowse link
G Ace2 angiotensin I converting enzyme 2 increases expression
increases activity
EXP Lisinopril results in increased expression of ACE2 mRNA
Lisinopril results in increased activity of ACE2 protein
CTD PMID:15897343, PMID:16221218 NCBI chr  X:32,050,734...32,095,860
Ensembl chr  X:32,049,931...32,096,016
JBrowse link
G Ache acetylcholinesterase multiple interactions ISO
EXP
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]
Lisinopril inhibits the reaction [Sodium Fluoride results in decreased activity of ACHE protein]
CTD PMID:23060470, PMID:31710167 NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
JBrowse link
G Agt angiotensinogen decreases expression
multiple interactions
decreases secretion
increases secretion
affects response to substance
increases expression
ISO
EXP
Lisinopril results in decreased expression of AGT protein
[Lisinopril co-treated with Losartan] results in increased expression of AGT mRNA
Lisinopril results in decreased secretion of AGT protein
Lisinopril results in increased secretion of AGT protein alternative form
AGT gene alternative form affects the susceptibility to Lisinopril
Lisinopril results in increased expression of AGT mRNA
CTD PMID:8393685, PMID:8915971, PMID:15897343, PMID:16221218, PMID:16685205 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression ISO Lisinopril results in decreased expression of BCL2 CTD PMID:10075388 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Cd2ap CD2-associated protein multiple interactions EXP Lisinopril inhibits the reaction [Doxorubicin results in increased expression of CD2AP protein] CTD PMID:16636307 NCBI chr 9:20,794,680...20,858,438
Ensembl chr 9:20,765,296...20,858,504
JBrowse link
G Edn1 endothelin 1 decreases secretion ISO Lisinopril results in decreased secretion of EDN1 protein CTD PMID:19079593 NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
JBrowse link
G Gh1 growth hormone 1 multiple interactions EXP [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] CTD PMID:20051877 NCBI chr10:94,486,204...94,488,181
Ensembl chr10:94,486,205...94,488,180
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions EXP Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] CTD PMID:19225054 NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
JBrowse link
G Hpse heparanase multiple interactions EXP [Spironolactone co-treated with Lisinopril] inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HPSE protein] CTD PMID:19429930 NCBI chr14:10,534,358...10,576,686
Ensembl chr14:10,534,423...10,575,224
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression ISO Lisinopril results in increased expression of IGFBP1 protein CTD PMID:9663927 NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions EXP [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein] CTD PMID:20051877 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein] CTD PMID:23060470 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] CTD PMID:20051877 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nphs1 NPHS1 adhesion molecule, nephrin multiple interactions EXP Lisinopril inhibits the reaction [Doxorubicin results in decreased phosphorylation of NPHS1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NPHS1 protein] CTD PMID:16636307, PMID:19293598 NCBI chr 1:88,922,346...88,950,560
Ensembl chr 1:88,922,433...88,950,559
JBrowse link
G Nphs2 NPHS2 stomatin family member, podocin multiple interactions EXP Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 mRNA]; Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 protein] CTD PMID:16636307 NCBI chr13:73,929,136...73,941,522
Ensembl chr13:73,929,136...73,941,522
JBrowse link
G Nppa natriuretic peptide A decreases expression ISO Lisinopril results in decreased expression of NPPA protein CTD PMID:8393685 NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
JBrowse link
G Ren renin increases expression
multiple interactions
ISO
EXP
Lisinopril results in increased expression of REN protein
[Lisinopril co-treated with Losartan] results in increased expression of REN mRNA
Lisinopril results in increased expression of REN mRNA
CTD PMID:2550029, PMID:8915971, PMID:16221218 NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions EXP [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein] CTD PMID:20051877 NCBI chr  X:1,364,771...1,369,451
Ensembl chr  X:1,364,786...1,369,384
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions EXP Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of VEGFA protein] CTD PMID:19293598 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
royal jelly term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO royal jelly inhibits the reaction [Nicotine results in decreased expression of BCL2 mRNA] CTD PMID:30896085 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Casp3 caspase 3 multiple interactions ISO royal jelly inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA] CTD PMID:30896085 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cat catalase multiple interactions EXP
ISO
royal jelly inhibits the reaction [Cisplatin results in decreased activity of CAT protein]
royal jelly inhibits the reaction [Nicotine results in decreased activity of CAT protein]
CTD PMID:20369241, PMID:30896085 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions
increases activity
affects binding
ISO Estradiol inhibits the reaction [royal jelly binds to ESR1 protein]; royal jelly binds to and results in increased activity of ESR1 protein; royal jelly inhibits the reaction [Estradiol binds to ESR1 protein]
royal jelly results in increased activity of ESR1 protein
CTD PMID:15946813, PMID:17287592 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Esr2 estrogen receptor 2 multiple interactions
affects binding
ISO Estradiol inhibits the reaction [royal jelly binds to ESR2 protein]; royal jelly binds to and results in increased activity of ESR2 protein; royal jelly inhibits the reaction [Estradiol binds to ESR2 protein] CTD PMID:15946813, PMID:17287592 NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO royal jelly inhibits the reaction [Nicotine results in decreased expression of PCNA protein] CTD PMID:30896085 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
JBrowse link
G Tff1 trefoil factor 1 increases expression ISO royal jelly results in increased expression of TFF1 mRNA CTD PMID:15946813 NCBI chr20:9,892,124...9,895,984
Ensembl chr20:9,892,124...9,895,984
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO royal jelly inhibits the reaction [Nicotine results in increased expression of TRP53 mRNA] CTD PMID:30896085 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO
EXP
royal jelly results in increased expression of VEGFA mRNA CTD PMID:15946813, PMID:17287592 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19816
    role 19764
      application 19426
        refrigerant 17439
          ammonia 16959
            organic amino compound 16958
              amino acid 14085
                diamino acid 29
                  (2R,5S)-2,5-diaminohexanoic acid 0
                  (3R)-3,6-diaminohexanoic acid 0
                  (3S)-3,6-diaminohexanoic acid 0
                  (3S)-3,7-diaminoheptanoic acid 0
                  (3S,5S)-3,5-diaminohexanoic acid 0
                  2,4-diaminobutyric acid + 0
                  2,4-diaminopentanoic acid + 0
                  2,6-diamino-7-hydroxy-azelaic acid 0
                  3-aminoalanine + 0
                  L-BMAA 0
                  lysine + 29
Path 2
Term Annotations click to browse term
  CHEBI ontology 19816
    subatomic particle 19814
      composite particle 19814
        hadron 19814
          baryon 19814
            nucleon 19814
              atomic nucleus 19814
                atom 19814
                  main group element atom 19702
                    p-block element atom 19702
                      carbon group element atom 19608
                        carbon atom 19597
                          organic molecular entity 19597
                            organic group 18537
                              organic divalent group 18530
                                organodiyl group 18530
                                  carbonyl group 18436
                                    carbonyl compound 18436
                                      carboxylic acid 18114
                                        amino acid 14085
                                          diamino acid 29
                                            (2R,5S)-2,5-diaminohexanoic acid 0
                                            (3R)-3,6-diaminohexanoic acid 0
                                            (3S)-3,6-diaminohexanoic acid 0
                                            (3S)-3,7-diaminoheptanoic acid 0
                                            (3S,5S)-3,5-diaminohexanoic acid 0
                                            2,4-diaminobutyric acid + 0
                                            2,4-diaminopentanoic acid + 0
                                            2,6-diamino-7-hydroxy-azelaic acid 0
                                            3-aminoalanine + 0
                                            L-BMAA 0
                                            lysine + 29
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.